New York, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Childhood Absence Epilepsy Treatment Market Research Report by Drug, by Disease Type - Global Forecast ...
Bright Minds Biosciences Inc. (DRUG) has been able to initiate its phase 2 BREAKTHROUGH study using its 5-HT2C agonist BMB-101 for the treatment of adult patients with classic Absence Epilepsy and ...
Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.
BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012DEE: 63.3% ...
Absence seizures, common in children, present as brief lapses in awareness, often mistaken for daydreaming. These non-convulsive seizures involve staring spells and subtle movements, potentially ...
Researchers aimed to identify the characteristics, treatment pathways, and outcomes associated with epilepsy with eyelid myoclonia (EEM). Epilepsy with eyelid myoclonia (EEM) is a rare and ...
“Do you know why you shouldn’t talk to strangers?” asks a police officer standing at the front of a classroom to a room full of students. Emily’s hand shoots up and the teacher encourages her to ...
The multicenter retrospective study included 543 mostly White women of childbearing age with IGE according to International League Against Epilepsy (ILAE) diagnostic criteria — a population facing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback